title: Histologic and cytologic detection of endocrine and reproductive tract effects of exemestane in female rats treated for up to twenty-eight days.
abstract: The objective of this study was to determine the shortest period of time necessary to detect histologic evidence of estrous cycle disruption in Sprague-Dawley rats treated for up to 28 days with the aromatase inhibitor exemestane at 1,000 mg/kg. Rats were evaluated on day 5, 8, 15, or 29. Vaginal mucification, uterine and cervical epithelial atrophy, uterine luminal epithelial vacuolation, decreased uterine granulocytes, and hypertrophy/hyperplasia of mammary ducts and alveoli were noted by day 5 and persisted throughout the study. From day 8 to day 29, absence of recent basophilic corpora lutea, increased atresia of antral follicles, interstitial cell hyperplasia, and increased luteinized follicles were present in the ovaries of treated rats. Vaginal smears detected persistent diestrus, confirming estrous cycle disruption between days 5 and 8. Ovary and uterine weights were largely unaffected. Serum hormone levels were not useful due to the study design employed. Other effects of exemestane included decreased adrenal weights and decreased cell size in both the adrenal zona fasciculata and the pituitary pars distalis. While early histologic changes were evident on day 5, only after 8 days of treatment were findings considered sufficient to clearly identify exemestane-induced estrous cycle disruption using microscopy alone.
authors.affiliation: Pfizer Global Research and Development, Groton, Connecticut 06340, USA. michae1.1.mirsky@pfizer.com
authors.forename: Michael L
authors.initials: ML
authors.lastname: Mirsky
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Sivaraman
authors.forename: Christopher
authors.initials: C
authors.lastname: Houle
authors.forename: David M
authors.initials: DM
authors.lastname: Potter
authors.forename: Robert E
authors.initials: RE
authors.lastname: Chapin
authors.forename: Gregg D
authors.initials: GD
authors.lastname: Cappon
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects* / Q000473:pathology; D000730:Androstadienes / Q000633:toxicity*; D000818:Animals; D047072:Aromatase Inhibitors / Q000633:toxicity; D001284:Atrophy; D004031:Diestrus / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D005497:Follicular Cyst / Q000473:pathology; D006728:Hormones / Q000097:blood; D008321:Mammary Glands, Animal / Q000187:drug effects* / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D006080:Ovarian Follicle / Q000187:drug effects* / Q000473:pathology; D010902:Pituitary Gland / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D002577:Uterine Cervical Diseases / Q000139:chemically induced / Q000473:pathology; D014621:Vagina / Q000166:cytology / Q000473:pathology
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D006728:Hormones; C056516:exemestane